{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-10-23",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "discontinued_date": "09/09/2026",
      "update_type": "New",
      "initial_posting_date": "09/09/2026",
      "package_ndc": "0006-3856-02",
      "generic_name": "Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection",
      "contact_info": "800-672-6372",
      "related_info": "To be discontinued on or near late September 2026.",
      "update_date": "09/09/2026",
      "therapeutic_category": [
        "Anti-Infective"
      ],
      "dosage_form": "Injection",
      "presentation": "RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02)",
      "company_name": "Merck Sharp & Dohme LLC",
      "status": "To Be Discontinued"
    }
  ]
}